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RESEARCH

Cost Variability of Suggested Generic Treatment
Alternatives Under the Medicare Part D Benefit
Rajul A. Patel, PharmD, PhD; Mark P. Walberg, PharmD, PhD; Emily Tong, PharmD;
Florence Tan, PharmD; Ashley E. Rummel, PharmD; Joseph A. Woelfel, RPh, PhD;
Sian M. Carr-Lopez, PharmD; and Suzanne M. Galal, PharmD

ABSTRACT
BACKGROUND: The substitution of generic treatment alternatives for
brand-name drugs is a strategy that can help lower Medicare beneficiary
out-of-pocket costs. Beginning in 2011, Medicare beneficiaries reaching
the coverage gap received a 50% discount on the full drug cost of brandname medications and a 7% discount on generic medications filled during
the gap. This discount will increase until 2020, when beneficiaries will be
responsible for 25% of total drug costs during the coverage gap.
OBJECTIVE: To examine the cost variability of brand and generic drugs
within 4 therapeutic classes before and during the coverage gap for each
2011 California stand-alone prescription drug plan (PDP) and prospective
coverage gap costs in 2020 to determine the effects on beneficiary out-ofpocket drug costs.
METHODS: Equivalent doses of brand and generic drugs in the following
4 pharmacological classes were examined: angiotensin II receptor blockers (ARBs), bisphosphonates, HMG-CoA reductase inhibitors (statins), and
proton pump inhibitors (PPIs). The full drug cost and patient copay/coinsurance amounts during initial coverage and the coverage gap of each drug
was recorded based on information retrieved from the Medicare website.
These drug cost data were recorded for 28 California PDPs.
RESULTS: The highest cost difference between a brand medication and
a Centers for Medicare & Medicaid Services (CMS)-suggested generic
treatment alternative varied between $110.53 and $195.49 at full cost and
between $51.37 and $82.35 in the coverage gap. The lowest cost difference varied between $38.45 and $76.93 at full cost and between -$4.11
and $18.52 during the gap.
CONCLUSION: Medicare beneficiaries can realize significant out-of-pocket
cost savings for their drugs by taking CMS-suggested generic treatment
alternatives. However, due to larger discounts on brand medications made
available through recent changes reducing the coverage gap, the potential
dollar savings by taking suggested generic treatment alternatives during
the gap is less compelling and will decrease as subsidies increase.
J Manag Care Pharm. 2014;20(3):283-90
Copyright © 2014, Academy of Managed Care Pharmacy. All rights reserved.

What is already known about this subject
• In accordance with the Patient Protection and Affordable Care
Act signed in March 2010, Medicare beneficiaries will receive a
graduated manufacturer-paid point-of-sale discount on formulary covered brand-name medications when filled during the
coverage gap effective in 2011.
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• Additionally, a beneficiary’s Part D plan will also provide a
discount for generic medications filled during the coverage gap
effective in 2011.
• The coverage gap discount for both brand-name and generic
medications will increase until 2020, when beneficiaries will be
responsible for 25% of total drug costs during the coverage gap.
• Angiotensin II receptor blockers (ARBs), bisphosphonates, HMGCoA reductase inhibitors (statins), and proton pump inhibitors
(PPIs) are 4 highly utilized drug classes by Medicare beneficiaries; each of these classes contain therapeutically equivalent
brand and generic medications.

What this study adds
• The out-of-pocket cost variability of 4 drug classes (ARBs,
bisphosphonates, statins, and PPIs) during initial coverage and
the coverage gap was summarized for each stand-alone prescription drug plan available in California in 2011.
• With only 1 exception, out-of-pocket costs for generic medications remained less expensive alternatives to brand-name
medications, despite a larger subsidy for brand-name medications
during the coverage gap in 2011.
• We demonstrated that beneficiary costs may decrease in the coverage gap from the original Medicare coverage level, while placing
more financial pressure on the plans to incentivize patients.

R

esearch has established that a relationship exists
between an individual’s out-of-pocket (OOP) medication costs and drug utilization.1-4 As OOP drug costs
increase, individuals are less likely to visit pharmacies and
increasingly likely to delay or forgo filling their medications.1-4
The federal government’s introduction of Medicare Part D
provided seniors aged 65 years and older and other eligible
beneficiaries a unique opportunity to enroll in a prescription
drug plan. Following introduction of the Part D benefit in
2006, beneficiary drug utilization increased by 7%, and OOP
costs decreased by 16%, a testament to the program’s success.5
While Part D offsets prescription medication costs for many,
shortcomings remain in this federally directed program. Since
its inception in 2006, most Part D plans have had a period
during which the beneficiary is solely responsible for the
majority of prescription drug costs. This is called the coverage
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TABLE 1
Year
2006-2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020

Beneficiary Cost Responsibilities
in the Gap14
Brand Drugs (%)
Generic Drugs (%)
100
100
100% with $250 rebate
50
93
50
86
47.5
79
47.5
72
45
65
45
58
40
51
35
44
30
37
25
25

gap and is commonly referred to as the “donut hole.” The coverage gap starts after beneficiaries and their plans have spent
a predetermined amount on formulary covered drugs.6 Prior
to 2010, most beneficiaries were required to pay 100% of their
prescription medication costs when filled during the donut
hole.7 Higher OOP medication costs can be a major problem
for those beneficiaries with limited income and resources.1,3,4
Moreover, research has shown that a beneficiary’s inability to
afford medications during the donut hole can be linked to such
problematic medication behaviors as skipping doses, delaying
refills, using medications less frequently, stopping medications,
or going without certain basic necessities (e.g., food or rent) in
order to afford medications.1 Medication adherence has been
shown to be negatively correlated with patients’ OOP costs.2-4
Taira et al. (2006) reported that medication adherence
decreased as drug copayments increased among patients with
hypertension taking at least 1 antihypertensive medication.2 In
this study, patients were deemed to be adherent to their antihypertensive medications if their medication possession ratio
was > 80%. Using this definition of adherence, the odds ratio
(OR) for adherence was 0.76 with a $5 copayment; however,
with higher copayments (ranging from $20-$165), the OR for
adherence dropped to 0.48. Results suggested that the copayment amount is a strong predictor of patient adherence.2 The
same pattern emerged with respect to HMG-CoA reductase
inhibitors (statins)—lower patient copayments were positively
correlated with higher levels of medication adherence.3 A $10
increase in copayments for statins was associated with a 1.8%
reduction in adherence for new users and a 3% reduction in
adherence for continuing users.3 This finding suggests adoption of lower copayments may increase medication adherence
and should therefore be considered by plan administrators.3
Another study found that medication adherence in patients
decreased following a $5 systemwide increase in copayments
at Veterans Affairs medical centers.4 The long-term effect of
this nominal copayment change was a decrease in veterans’
284 Journal of Managed Care & Specialty Pharmacy
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adherence to oral hypoglycemic agents by 10.3%, antihypertensive agents by 5.4%, and statins by 1.9%.4 Clearly, reduced
adherence to long-term medications increases the likelihood of
significant and costly clinical events that ultimately increase
total health care costs.2-4
While there is little, if anything, beneficiaries can do to
lower manufacturer-set medication prices, increasing prescriber awareness of medication costs may be an integral step
in decreasing cost-related drug nonadherence. Prescriber
knowledge regarding medication costs was examined in a
survey-based study among 210 general practitioners. Of those
surveyed, 43% were found to have limited, if any, knowledge of
drug costs.8 Furthermore, the study suggested that prescribers
with inaccurate drug cost estimates were less likely than other
prescribers to exercise therapeutic substitution.8
A lack of effective communication also exists between prescribers and patients with regards to concerns of medication
affordability. A survey of 17,569 Medicare beneficiaries in 2003
revealed that 26.3% had cost-related medication nonadherence.9 Of those, 61% expressed concerns about their medication costs to their physicians, and only 38.1% were switched
to a cheaper alternative by their physicians.9 In a nationwide
survey of adults with chronic illnesses who admitted to costrelated medication underutilization, two-thirds claimed never
discussing planned cost-related underuse with their physicians, and over half did not believe their providers could help.10
Even when patients discussed medication costs with their
physicians, fewer than 1 in 3 said their physicians made any
attempt to address their cost-related concerns.10
Another aspect to this issue involves patients’ willingness to
pay more for brand-name medications. A survey of members
in a large managed care organization in the western United
States was conducted, and participants with a chronic disease (i.e., hypertension, diabetes, dyslipidemia, arthritis, or
gastroesophageal reflux disease) were asked if they would be
willing to pay extra for a brand-name medication. Half of the
respondents were willing to pay extra, even if a generic equivalent was available.11 However, there appeared to be a financial
threshold, as a majority indicated reluctance to pay more than
an additional $10 per month for a brand-name medication,
when a less expensive alternative was available.11
While some patients may desire brand-name drugs, OOP
costs can be a contributing factor to adherence. Claims data
for new prescriptions of generic or brand-only drug therapy
were analyzed for medication adherence among patients with
specific medical conditions. Generic drugs were associated
with significantly greater adherence than brand-name drugs in
patients with hypercholesterolemia (62% vs. 53%) but surprisingly significantly lower adherence in patients with hypertension (47% vs. 59%).12 No significant difference in adherence
rates between generic and brand medications was found for
the other investigated conditions, including seizure disorders,
hypothyroidism, and type 2 diabetes.12 The study authors did
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TABLE 2

ARBs: Average (SD) Costs of Brand-Name Medications and Suggested
Generic Treatment Alternatives Under 2011 California PDPs
$ in SBP/DBP (mm Hg)b

Druga

7-8/4-5
8-10/5-6
10-12/6-7
12-13/7-8
Dose
4 mg
8 mg
16 mg
32 mg
Total drug cost ($)
71.97
(4.19)
71.97
(4.19)
71.97
(4.19)
71.97
(4.19)
Candesartanc
Initial coverage ($)
57.57 (22.15)
57.57 (22.15)
57.57 (22.15)
57.57 (22.15)
(n = 7)
Coverage gap ($)
36.95
(2.04)
36.95
(2.04)
36.95
(2.04)
36.95
(2.04)
2020 gap ($)
17.99
(1.05)
17.99
(1.05)
17.99
(1.05)
17.99
(1.05)
Dose
400 mg
600 mg
Total drug cost ($)
90.85
(5.07)
106.10
(5.87)
Eprosartanc
Initial coverage ($)
83.88
(4.66)
83.88
(4.66)
(n = 4)
Coverage gap ($)
46.21
(2.68)
53.80
(3.08)
2020 gap ($)
22.71
(1.27)
26.53
(1.47)
Dose
75 mg
150 mg
300 mg
Total drug cost ($)
78.06
(3.83)
82.08
(4.04)
98.24
(4.87)
Irbesartanc
Initial coverage ($)
39.32
(24.25)
40.09
(24.69)
41.74
(23.81)
(n = 10)
Coverage gap ($)
40.00
(1.93)
42.00
(2.03)
50.09
(2.42)
2020 gap ($)
19.52
(0.96)
20.52
(1.01)
24.56
(1.22)
Dose
25 mg
50 mg
100 mg
Losartan
Total drug cost ($)
20.30
(11.84)
25.36 (15.31)
33.60 (21.86)
(25 mg: n = 26;
Initial coverage ($)
6.23
(5.17)
6.36
(5.67)
6.75
(6.10)
50 mg and
Coverage
gap
($)
17.34
(11.33)
21.28
(14.80)
28.12
(21.09)
100 mg: n = 27)
2020 gap ($)
5.08
(2.96)
6.34
(3.83)
8.40
(5.46)
Dose
5 mg
20 mg
40 mg
Total drug cost ($)
67.23
(3.08)
81.74
(3.78)
113.04
(5.32)
Olmesartanc
Initial coverage ($)
38.29
(16.16)
42.68
(19.77)
49.96
(19.53)
(n = 11)
Coverage gap ($)
34.64
(1.58)
41.63
(2.43)
57.55
(2.62)
2020 gap ($)
16.81
(0.77)
20.43
(0.95)
28.26
(1.33)
Dose
20 mg
40 mg
80 mg
Total drug cost ($)
99.37
(4.60)
99.37
(4.60)
99.37
(4.60)
Telmisartanc
Initial coverage ($)
43.53 (22.81)
43.53 (22.81)
43.53 (22.81)
(n = 18)
Coverage gap ($)
50.57
(2.62)
50.57
(2.62)
50.57
(2.62)
2020 gap ($)
24.84
(1.15)
24.84
(1.15)
24.84
(1.15)
Dose
40 mg
80 mg
160 mg
320 mg
Valsartanc
Total drug cost ($)
130.80 (23.91)
81.88
(3.34)
87.89
(3.58)
110.61
(4.41)
(40 mg and
320 mg: n = 27;
Initial coverage ($)
42.71
(16.03)
35.76
(13.16)
37.46
(14.25)
40.57
(16.29)
80 mg and
Coverage gap ($)
68.71
(2.94)
41.89
(1.98)
44.89
(2.09)
56.26
(2.46)
160 mg: n = 26)
2020 gap ($)
32.70
(5.98)
20.47
(0.84)
21.97
(0.90)
27.65
(1.10)
an indicates number of PDPs with medication on plan formulary.
bBlood pressure decrease based on Medicare Plan Finder Tool equivalency tables and package insert data.
cIndicates drug was available brand only at the time of data pull.
ARB = angiotensin II receptor blockers; DBP = diastolic blood pressure; mg =milligram; mm Hg = millimeter of mercury; PDP = prescription drug plan; SBP = systolic blood
pressure; SD = standard deviation.

not identify any concrete reasons for these results but did find
that $0 copayment amounts were related to increased medication adherence regardless of the individual’s medical condition
or whether the medication in question was generic or brand.12
These findings may indicate that any OOP costs may decrease
adherence.
Starting in 2011, in accordance with the Patient Protection
and Affordable Care Act, Medicare beneficiaries received a 50%
manufacturer-paid point-of-sale copay discount off the total
cost of the drug on formulary covered brand-name medications
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when filled during the coverage gap.13 Additionally, in 2011,
a beneficiary’s Part D plan discounted generic medications
by 7% of the total drug cost, when filled during the coverage gap.6 To date, no studies have examined the cost difference between brand-name medications and suggested generic
treatment alternatives during the coverage gap under Part D.
This coverage gap discount is set to increase until 2020, when
beneficiaries will be responsible for 25% of total drug costs for
both brand and generic medications (Table 1). Manufacturers
will still be responsible for 50%, and the Part D plan will then
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TABLE 3

Bisphosphonates: Average (SD) Costs of Brand-Name Medications and
Suggested Generic Treatment Alternatives Under 2011 California PDPs
Regimen

Druga

Daily

Dose (quantity)
5 mg (30)
Alendronate
Total drug cost ($)
28.60 (18.48)
(5 mg, 35 mg,
Initial coverage ($)
4.95 (3.33)
70 mg: n = 28;
Coverage
gap
($)
21.20
(18.32)
10 mg: n = 26)
2020 gap ($)
7.15 (4.62)
Dose (quantity)
5 mg (30)
Total drug cost ($)
114.47 (3.93)
Risedronateb
Initial coverage ($)
61.29 (23.37)
(n = 16)
Coverage gap ($)
58.18 (2.07)
2020 gap ($)
28.62 (0.98)
Dose (quantity)
Total drug cost ($)
Ibandronateb
Initial coverage ($)
(n = 23)
Coverage gap ($)
2020 gap ($)
an indicates number of PDPs with medication on plan formulary.
bIndicates drug was available brand only at the time of data pull.
mg = milligram; PDP = prescription drug plan; SD = standard deviation.

10 mg (30)
25.16 (16.06)
5.15 (2.99)
17.82 (15.22)
6.29 (4.01)

be responsible for the remaining 25% of total brand drug costs
during the gap.14 This cost-sharing arrangement means that
plans and beneficiaries will both have the same “skin in the
game” during the coverage gap.
In this study, we analyzed beneficiary cost data of various
suggested generic treatment alternatives. The objective of the
present research was to determine cost disparities of brandname medications and equipotent suggested generic treatment
alternatives during the coverage gap for drugs in 4 pharmacological classes: angiotensin II receptor blockers (ARBs),
bisphosphonates, HMG-CoA reductase inhibitors (statins), and
proton pump inhibitors (PPIs). Additionally, the future coverage gap drug costs in 2020 for beneficiaries and drug plans
were estimated.
■■ Methods
Four pharmacological drug classes (ARBs, bisphosphonates,
statins, and PPIs) were chosen based on high utilization patterns by beneficiaries for treatment of common chronic conditions and the presence of suggested alternative brand-only
and generic medications that existed within each class. Livalo
(pitavastatin) was available in 2011 but did not have any cost
data available on the Medicare website during the data collection period and was therefore excluded from the study. Dose
equivalence for brand and generic drugs in all 4 classes was
established using dose equivalency tables from the Medicare
website and verified through examination of published literature and drug monographs.
286 Journal of Managed Care & Specialty Pharmacy
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Weekly
35 mg (4)
70 mg (4)
18.76 ($15.80)
18.39 (14.39)
4.54 ($3.21)
4.14 (2.72)
15.50 ($15.53)
14.39 (14.16)
4.69 ($3.95)
4.60 (3.60)
35 mg (4)
106.95 (3.67)
60.49 (24.08)
54.41 (1.95)
26.74 (0.92)

Monthly

150 mg (1)
115.70 (3.97)
61.42 (23.26)
58.79 (2.08)
28.92 (0.99)
150 mg (1)
115.02 (4.19)
42.72 (13.56)
58.51 (2.51)
28.76 (1.05)

The data collection period for this cross-sectional observational study commenced in January 2011 and ended in April
2011. Drugs from each of the 4 examined classes were entered
into the Medicare Plan Finder Tool (available at https://www.
medicare.gov/find-a-plan/questions/home.aspx). Alternative
brand and generic medications were recorded from the Plan
Finder Tool’s “Lower Your Drug Costs” link available on the
Plan Results page. This function is available for certain drugs
that have alternative medications within the same drug class
and allows users to view alternative equivalent doses of brand
and generic medications within the same class and their
respective costs under each plan. Next, the full drug cost and
cost during the coverage gap as listed on the Medicare website
was recorded for all 2011 California stand-alone prescription drug plans (PDPs). Although 33 PDPs were available in
California in 2011, data from only 28 plans were available on
the Medicare website during the data collection period. Plan
drug costs were included in the analysis if the drug was on the
plan’s formulary.
The beneficiary’s OOP cost during initial coverage and the
coverage gap listed on the Medicare website for each analyzed
medication was averaged across all available 2011 California
PDPs that included it on their formularies. The estimated 2020
coverage gap cost for both beneficiaries and Part D plans was
estimated by multiplying each drug’s total cost by 25% and then
averaging across all PDPs listing it as a formulary medication.
Descriptive statistics were used to summarize drug cost
data. Data analyses were performed using SPSS, version 18.0
(Chicago, IL).
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■■ Results
A total of 7 ARBs (candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan); 3 bisphosphonates (alendronate, ibandronate, and risedronate); 6 PPIs
(dexlansoprazole, esomeprazole, lansoprazole, omeprazole,
pantoprazole, and rabeprazole); and 6 statins (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin)
were examined. Tables 2-5 highlight the full initial coverage,
2011 coverage gap, and 2020 coverage gap costs (mean [SD])
of brand name and suggested generic treatment alternatives
under the 28 available California PDPs in 2011.
Table 2 reveals that the costs of both candesartan and
telmisartan were dose independent. Valsartan was unique in
that the lowest and highest available strengths of the drug are
more costly than other available strengths. During the coverage
gap, brand-name drugs cost between $8.83 and $51.37 more
than suggested generic treatment alternatives. Estimated 2020
coverage gap costs were lower than current copay amounts
for all ARBs, except for lostartan (the only ARB available as a
generic at the time of this study).
Cost data for orally administered bisphosphonates with
daily, weekly, and monthly dosing regimens are presented in
Table 3. Minimal cost differences were noted between different dosing regimens for each medication. Generically available
alendronate 70 milligrams (mg) had the lowest OOP cost during the coverage gap in 2011 and as estimated for 2020. For
all 3 dosing regimens, risedronate had higher average copay/
coinsurance amounts during the initial coverage level than
during the 2011 or estimated 2020 coverage gap periods. No
intravenous bisphosphonates were included, since these are
billed to Medicare Part B, not Part D.
Equipotent doses of PPIs can be found in Table 4. The
total drug cost difference between brands and suggested
generic treatment alternatives ranged from $41.91 to $195.49.
During the 2011 donut hole, the lowest cost brand-name drug
(Dexilant, or dexlansoprazole, 30 mg, average [SD] coinsurance cost of $65.43 [$2.28]) was actually less expensive than
the highest priced generic alternative (lansoprazole 15 mg,
average [SD] coinsurance cost of $69.54 [$21.79]). This scenario was found to be true with the higher doses of Dexilant
(dexlansoprazole) 60 mg and lansoprazole 30 mg, as well. For
all PPIs (except rabeprazole), the drug cost or copay/coinsurance amounts were similar or identical between the different
strengths.
Table 5 highlights cost differences for brand and generic
statins. The full drug cost of statins is largely independent of
dose, although large price increases are seen with the highest
doses of fluvastatin and lovastatin and between the lowest
dose of atorvastatin and all other doses of the drug. The cost
difference between brand and generic alternatives during the
coverage gap varied from $18.52 to $78.89. Brand-name statins
were estimated to be less expensive during the 2020 coverage
gap than the 2011 initial coverage copay/coinsurance amounts.
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TABLE 4

PPIs: Average (SD) Costs of BrandName Medications and Suggested
Generic Treatment Alternatives
Under 2011 California PDPs

Druga

Low Dose
High Dose
Dose
30 mg
60 mg
Total drug cost ($) 129.14 (4.07) 129.14 (4.07)
Dexlansoprazoleb
Initial coverage ($)
56.86 (24.21)
56.86 (24.21)
(n = 24)
Coverage gap ($)
65.43 (2.28)
65.03 (3.29)
2020 gap ($)
32.28 (1.02)
32.28 (1.02)
Dose
20 mg
40 mg
Total drug cost ($) 183.98 (8.35) 183.98 (8.35)
Esomeprazoleb
Initial coverage ($)
41.09 (6.74)
41.09 (6.74)
(n = 22)
Coverage gap ($)
92.80 (4.42)
92.80 (4.42)
2020 gap ($)
46.00 (2.09)
46.00 (2.09)
Dose
15 mg
30 mg
Total drug cost ($)
78.26 (16.39)
74.52 (12.92)
Lansoprazole
Initial coverage ($)
24.38 (17.93)
24.35 (17.95)
(n = 19)
Coverage gap ($)
69.54 (21.79)
66.04 (18.91)
2020 gap ($)
19.56 (4.10)
18.63 (3.23)
Dose
20 mg
40 mg
Total drug cost ($)
25.24 (21.30)
29.27 (24.25)
Omeprazole
Initial coverage ($)
5.23 (4.44)
5.54 (4.39)
(n = 28)
Coverage gap ($)
20.56 (21.18)
23.83 (23.83)
2020 gap ($)
6.31 (5.33)
7.32 (6.06)
Dose
20 mg
40 mg
Total drug cost ($)
69.54 (35.74)
68.48 (34.49)
Pantoprazole
Initial coverage ($)
22.08 (23.34)
22.04 (23.33)
(n = 14)
Coverage gap ($)
58.65 (35.77)
58.04 (34.86)
2020 gap ($)
17.39 (8.93)
17.12 (8.62)
Dose
20 mg
Total drug cost ($)
209.86 (0)
b
Rabeprazole
Initial coverage ($)
92.34 (32.65)
(n = 2)
Coverage gap ($)
106.18 (0)
2020 gap ($)
52.47 (0)
an indicates number of PDPs with medication on plan formulary.
bIndicates drug was available brand only at the time of data pull.
mg = milligram; PDP = prescription drug plan; PPI = proton pump inhibitors;
SD = standard deviation.

At the time of this study, atorvastatin was only available as a
brand-name drug.
■■ Discussion
Our study revealed that the cost disparity between brand
and generic medications filled prior to the gap is decreased
considerably once the beneficiary reaches the coverage gap.
In 2011, 7.9% of Medicare beneficiaries reached the coverage
gap, receiving over $2.3 billion collectively in coverage gap
discounts.15 The absolute beneficiary cost difference between
brand-name medications and generic alternatives should continue to shrink each year (plateauing in 2020), as an increasing
percentage of a beneficiary’s formulary covered medication
costs are subsidized during the gap. Beneficiary OOP gap
costs for 2020 were estimated in this study and indicated that
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TABLE 5

Statins: Average (SD) Costs of Brand-Name Medications and Suggested
Generic Treatment Alternatives Under 2011 California PDPs
% LDL decreaseb

Druga
Fluvastatinc
(n = 10)

Lovastatin
(10 mg: n = 23;
20 mg and
40 mg: n = 25;
80 mg: n = 26)

Dose
Total drug cost ($)
Initial coverage ($)
Coverage gap ($)
2020 gap ($)
Dose

15%-19%
20 mg
98.15 (4.69)
55.95 (24.82)
50.03 (2.28)
24.54 (1.17)
10 mg

20%-30%
31%-39%
40 mg
80 mg
98.15 (4.69) 190.99 (6.65)
55.95 (24.82) 63.94 (26.49)
50.03 (2.28) 96.44 (3.42)
24.54 (1.17) 47.75 (1.66)
20 mg
40 mg

40%-45%

46%-49%

50%-54%

55%+

80 mg
(40 mg BID)
62.60 (71.06)
5.29 (3.53)
52.30 (69.26)
15.65 (17.77)
80 mg
31.36 (24.19)
4.75 (2.99)
24.29 (25.00)
7.84 (6.05)
40 mg
80 mg
22.22 (28.04) 22.67 (27.41)
4.08 (2.74)
4.32 (2.88)
18.30 (27.09) 18.65 (26.56)
5.56 (7.01)
5.67 (6.85)
20 mg
40 mg
80 mg
153.49 (6.31) 153.38 (6.19) 153.38 (6.19)
40.09 (17.77) 39.66 (17.48) 39.66 (17.48)
77.62 (3.27) 77.57 (3.21) 77.57 (3.21)
38.37 (1.58) 38.35 (1.55) 38.35 (1.55)
5 mg
10 mg
20 mg
40 mg
139.53 (6.07) 139.53 (6.07) 139.53 (6.07) 139.16 (5.95)
39.34 (20.87) 39.34 (20.87) 39.34 (20.87) 38.60 (20.20)
70.82 (3.08) 70.82 (3.08) 70.82 (3.08) 70.63 (3.18)
34.88 (1.52) 34.88 (1.52) 34.88 (1.52) 34.79 (1.49)

Total drug cost ($)
13.56 (7.08) 17.08 (13.28) 24.62 (23.64)
Initial coverage ($)
4.09 (3.05)
4.41 (3.04)
4.71 (3.00)
Coverage gap ($)
11.26 (7.54) 14.32 (13.14) 19.45 (21.68)
2020 gap ($)
3.39 (1.77)
4.27 (3.32)
6.15 (5.91)
Dose
10
mg
20
mg
40 mg
Pravastatin
Total drug cost ($)
17.99 (17.12) 17.90 (17.50) 22.87 (26.29)
(10 mg and
20 mg: n = 28;
Initial coverage ($)
4.35 (2.96)
4.33 (2.96)
4.38 (2.94)
40 mg and
Coverage gap ($)
15.01 (16.75) 15.03 (16.98) 19.07 (25.48)
80 mg: n = 27)
2020 gap ($)
4.50 (4.28)
4.47 (4.37)
5.72 (6.57)
Dose
5 mg
10 mg
20 mg
Simvastatin
Total drug cost ($)
16.26 (11.69) 17.65 (15.87) 22.01 (28.19)
(5 mg, 20 mg,
40 mg: n = 26;
Initial coverage ($)
4.01 (2.72)
3.73 (2.76)
3.95 (2.80)
10 mg: n = 24;
Coverage gap ($)
12.78 (11.72) 14.35 (15.69) 18.28 (27.16)
80 mg: n = 27)
2020 gap ($)
4.07 (2.92)
4.41 (3.97)
5.50 (7.05)
Dose
10 mg
Atorvastatinc
Total drug cost ($)
112.18 (14.86)
(10 mg, 40 mg,
Initial coverage ($)
36.67 (16.10)
80 mg: n = 23;
Coverage gap ($)
57.06 (7.59)
20 mg: n = 22)
2020 gap ($)
28.05 (3.72)
Dose
Rosuvastatinc
Total drug cost ($)
(5 mg, 10 mg,
Initial coverage ($)
20 mg: n = 23;
Coverage
gap ($)
40 mg: n = 25)
2020 gap ($)
an indicates number of PDPs with medication on plan formulary.
bLDL decrease based on Medicare Plan Finder Tool equivalency tables and package insert data.
cIndicates drug was available brand only at the time of data pull.
BID = twice daily; LDL = low-density lipoprotein; mg = milligram; PDP = prescription drug plan; SD = standard deviation; statin = HMG-CoA reductase inhibitor.

generics will still remain less expensive than brand-name medications; however, copay/coinsurance amounts in the 2020 coverage gap were estimated to be lower than current OOP costs
during the initial coverage phase (generally the least expensive
coverage level of the Medicare Part D benefit).
As expected, the cost difference between brand-name medications and equipotent doses of suggested generic treatment
alternatives was far less when filled during the gap. However,
unexpectedly, we also found that in 1 instance filling a brandname medication (Dexilant [dexlansoprazole]) would have
been less expensive than filling a suggested generic treatment
alternative (lansoprazole) during the gap across the examined
PDPs. This finding may be explained by the late entry of dexlansoprazole to the market and the competitive pricing by its
288 Journal of Managed Care & Specialty Pharmacy
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manufacturer to help increase market share. Another possible
contributor to this finding is that generic lansoprazole became
available in late 2009, and the cost disparity between the
brand-name medication (Prevacid) and its generic alternative
(lansoprazole) may have been at its lowest level at that point
in time.
The decrease in cost disparity between brand-name medications and suggested generic treatment alternatives may change
beneficiary behavior. As previous research has suggested,
patients are willing to pay nominally more for brand-name
medications when a cheaper generic alternative is available.11
Based on these findings, one could infer that upon reaching
the gap, there may be less financial pressure to switch from
a higher cost brand-name medication to a less expensive
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suggested generic treatment alternative from the same medication class. The result of such behavior might be increased and
unnecessary medications costs that are paid for by private plan
sponsors and/or the Medicare program. This behavior may
be enhanced by the low OOP costs observed in the estimated
2020 coverage gap costs, which were lower than the average
initial coverage copay/coinsurance amounts for all brand-name
drugs included in this study, except esomeprazole. This would
also increase the cost to the PDP, since the plan will be responsible for an equivalent amount (25% of brand-name medications) during the coverage gap in 2020.
The estimated 2020 coverage gap costs presented in this
study (Tables 2-5) are the costs to both the beneficiary and the
PDP. In 2013 and 2014, PDPs become responsible for 2.5% of
total brand-name drug costs in the coverage gap with a rapid
increase to 25% by 2020 (Table 1), indicating a financial incentive for plans to keep beneficiaries from reaching the coverage
gap. This is counter to the lower beneficiary OOP costs during
the 2020 coverage gap as compared with the 2011 copay/coinsurance amounts in the initial coverage phase. This opposing
financial incentive may lead to increased utilization of brandname medications during the gap and increased PDP costs if
patients do not switch to suggested generic alternatives. While
many of the brand-name medications examined in this study
have already gone generic at the time of publication, and many
more will by 2020, the medications included in this study are a
small sample of the multitude of drug classes that will continue
to have brand-name only medications. As has been observed
with premiums in the wake of the Patient Protection and
Affordable Care Act, the effects of copay/coinsurance subsidization during the coverage gap may cause an increase in beneficiary OOP costs during the initial coverage phase to allow for
PDPs to recoup the increased expense during the coverage gap.
Future studies examining the fill rates of brand-name medications and suggested generic treatment alternatives before,
during, and after the coverage gap would enable assessment
as to whether beneficiary and/or prescriber behavior changes
during each of these different phases of the Medicare benefit.
Using a claims database to retrospectively examine Medicare
beneficiary adherence and medication switching in response
to price changes and the impact of generic substitutions would
allow for the examination of the effects on health care reform
policies.
Limitations
First, only 28 of the 33 California PDPs available in 2011 were
included in data collection due to lack of availability of plan
information for the other 5 plans on the Medicare website.
Second, the collected data were specific for the changes in
Medicare being implemented in 2011. Therefore, it is possible
that the results may differ in subsequent years based on annual
changes that occur to the Medicare benefit and changes in
drug costs. Third, the cost data collected were specific for PDPs
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offered in California and may not be generalizable nationally.
Fourth, the estimated coverage gap costs for 2020 do not take
into account unknown and incalculable changes to brand and
generic drug prices and are calculated based on 2011 total drug
costs. We recommend that future studies be conducted to see
if our results are replicable in the other 33 Medicare regions.
Lastly, this study does not account for possible discount programs (e.g., $4 generics) that beneficiaries can utilize to reduce
OOP costs outside of their PDP benefits.
These limitations notwithstanding, this is the first study
known to examine the cost difference between brand-name
medications and suggested generic treatment alternatives
during the coverage gap and to estimate the costs to beneficiaries and Part D plans when the full discount is implemented
in 2020.
■■ Conclusions
Medicare beneficiaries can realize significant costs savings by
taking suggested generic treatment alternatives prior to the
coverage gap. Additionally, due to larger discounts on brand
medications, the potential dollar savings by taking suggested
generic treatment alternatives during the gap is less financially
compelling from a beneficiary’s perspective, especially as the
coverage gap subsidy increases in future years. While beneficiary copayment increases indirectly correlate with medication
adherence rates, current policy and practices may incentivize
brand-name medication use during the coverage gap, placing
PDPs at a financial disadvantage when suggested generic treatment alternative medications are available.
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